Search - tctmd.com

Displaying 181 - 200 of 397

Sort: Relevancy | Date

Presentation TCT 2016

Should Bivalirudin Only Be Used With a Prolonged Post-PCI Infusion?

Presenter: A. Michael Lincoff, Franz-Josef Neumann, Gregg W. Stone

October 30, 2016

Presentation TCT 2016

BIONICS: A Prospective, Randomized Trial of a Ridaforolimus-Eluting Coronary Stent vs a Zotarolimus-Eluting Stent in a More-Comers Population of Patients With Coronary Artery Disease

Presenter: Gregg W. Stone, Wayne B. Batchelor, David E. Kandzari

October 30, 2016

Presentation TCT 2016

BIO-RESORT (TWENTE III): A Prospective, Randomized Three-Arm Trial Comparing Two Different Biodegradable Polymer-Based Drug-Eluting Stents and a Durable Polymer-Based Drug-Eluting Stent in an All-Comers Population of Patients With Coronary Artery Disease

Presenter: Gregg W. Stone, Wayne B. Batchelor, Clemens von Birgelen

October 30, 2016

Presentation TCT 2016

ILUMIEN III (OPTIMIZE PCI): A Prospective, Randomized Trial of OCT-Guided vs IVUS-Guided vs Angio-Guided Stent Implantation in Patients With Coronary Artery Disease

Presenter: Gregg W. Stone, Wayne B. Batchelor, Ziad A. Ali

October 30, 2016

News Opinion Editor's Corner TCT 2016

TCT 2016: Inspiration and Perspiration Greet Left Main Stenting, Hoop Dreams, Valve Innovation, and Election Fever

Shelley Wood

October 24, 2016

Presentation TCT 2015

Debate: Should Our Patients Receive BRS Rather Than Metallic DES TODAY? Yes, the 1-Year Results Are Very Close, and the Late Outcomes Will Be Superior Our Patients Cant Wait for the Proof!

Presenter: Thomas F. Luscher, Gregg W. Stone, Ashok Seth

October 15, 2015

Presentation TCT 2015

Case Resolution: How We Treated a Clinically High-Risk and Anatomically Complex Left Main Patient (With Long-term Follow-up)

Presenter: Davide Capodanno, Gregg W. Stone, Nicholas J. Lembo

October 15, 2015

Presentation TCT 2015

Case Introduction: PCI or CABG? A Clinically High-Risk and Anatomically Complex Left Main Patient

Presenter: Davide Capodanno, Gregg W. Stone, Nicholas J. Lembo

October 15, 2015

Presentation TCT 2015

Who Should Undergo LM PCI Today? US and EU Guidelines and AUC Review

Presenter: Davide Capodanno, Gregg W. Stone, Ajay J. Kirtane

October 15, 2015

Presentation TCT 2015

Long-term Results of PCI vs CABG in 4,046 Patients With Left Main Disease: Fu Wai Experience

Presenter: Davide Capodanno, Gregg W. Stone, Bo Xu

October 15, 2015

Presentation TCT 2015

PCI vs CABG for LM Disease: New Insights From Syntax LM to Help Choose

Presenter: Davide Capodanno, Gregg W. Stone, Patrick W. Serruys

October 15, 2015

Presentation TCT 2015

Left Main PCI vs CABG: Fifteen-Year Results From the Asan Medical Center and 5-Year Results From PRECOMBAT

Presenter: Davide Capodanno, Gregg W. Stone, Jung-Min Ahn

October 15, 2015

Presentation TCT 2015

Possible Clinical Trial Designs to Demonstrate the Relative Benefits of BRS vs Permanent Platform DES

Presenter: Chuck Simonton, Gregg W. Stone

October 14, 2015

Presentation TCT 2015

Incorporating Quality-of-Life and Patient-Oriented Outcomes in the Device Regulatory Approval Process

Presenter: Andrew Farb, Gregg W. Stone, John A. Spertus

October 14, 2015

Presentation TCT 2015

Key Elements of BRS Nonclinical Testing to Support IDE Approval

Presenter: Andrew Farb, Gregg W. Stone, Michael C. John

October 14, 2015

Presentation TCT 2015

Controversial Viewpoint: Characterizing BRS Class Effects BRS Designs Are More Different Than Alike (Regulatory Implications)

Presenter: Andrew Farb, Gregg W. Stone, Juan F. Granada

October 14, 2015

Presentation TCT 2015

Assessing Whether Superiority Exists: Design, Rationale, and Status of ABSORB IV

Presenter: Stephen G. Ellis, Patrick W. Serruys, Gregg W. Stone

October 14, 2015

Presentation TCT 2015

Featured Lecture: One-Year Patient-Level Pooled Meta-analysis From 4 ABSORB Trials in 3389 Randomized Patients

Presenter: Stephen G. Ellis, Patrick W. Serruys, Gregg W. Stone

October 14, 2015

Presentation TCT 2015

Identifying and Studying Data Gaps: Cangrelor Use What's Settled, and What's Not?

Presenter: Deepak L. Bhatt, Martin Rose, Gregg W. Stone

October 14, 2015

Presentation TCT 2015

When and How to Treat a Claudicant With an Occluded SFA

Presenter: William A. Gray, Gregg W. Stone, D. Christopher Metzger, Herbert D. Aronow

October 14, 2015

Advertisement

Should Bivalirudin Only Be Used With a Prolonged Post-PCI Infusion?

BIONICS: A Prospective, Randomized Trial of a Ridaforolimus-Eluting Coronary Stent vs a Zotarolimus-Eluting Stent in a More-Comers Population of Patients With Coronary Artery Disease

BIO-RESORT (TWENTE III): A Prospective, Randomized Three-Arm Trial Comparing Two Different Biodegradable Polymer-Based Drug-Eluting Stents and a Durable Polymer-Based Drug-Eluting Stent in an All-Comers Population of Patients With Coronary Artery Disease

ILUMIEN III (OPTIMIZE PCI): A Prospective, Randomized Trial of OCT-Guided vs IVUS-Guided vs Angio-Guided Stent Implantation in Patients With Coronary Artery Disease

TCT 2016: Inspiration and Perspiration Greet Left Main Stenting, Hoop Dreams, Valve Innovation, and Election Fever

Debate: Should Our Patients Receive BRS Rather Than Metallic DES TODAY? Yes, the 1-Year Results Are Very Close, and the Late Outcomes Will Be Superior Our Patients Cant Wait for the Proof!

Case Resolution: How We Treated a Clinically High-Risk and Anatomically Complex Left Main Patient (With Long-term Follow-up)

Case Introduction: PCI or CABG? A Clinically High-Risk and Anatomically Complex Left Main Patient

Who Should Undergo LM PCI Today? US and EU Guidelines and AUC Review

Long-term Results of PCI vs CABG in 4,046 Patients With Left Main Disease: Fu Wai Experience

PCI vs CABG for LM Disease: New Insights From Syntax LM to Help Choose

Left Main PCI vs CABG: Fifteen-Year Results From the Asan Medical Center and 5-Year Results From PRECOMBAT

Possible Clinical Trial Designs to Demonstrate the Relative Benefits of BRS vs Permanent Platform DES

Incorporating Quality-of-Life and Patient-Oriented Outcomes in the Device Regulatory Approval Process

Key Elements of BRS Nonclinical Testing to Support IDE Approval

Controversial Viewpoint: Characterizing BRS Class Effects BRS Designs Are More Different Than Alike (Regulatory Implications)

Assessing Whether Superiority Exists: Design, Rationale, and Status of ABSORB IV

Featured Lecture: One-Year Patient-Level Pooled Meta-analysis From 4 ABSORB Trials in 3389 Randomized Patients

Identifying and Studying Data Gaps: Cangrelor Use What's Settled, and What's Not?

When and How to Treat a Claudicant With an Occluded SFA

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content